Trends of rubella incidence during a 5-year period of case based surveillance in Zimbabwe by Simbarashe Chimhuya et al.
Chimhuya et al. BMC Public Health  (2015) 15:294 
DOI 10.1186/s12889-015-1642-4RESEARCH ARTICLE Open AccessTrends of rubella incidence during a 5-year period
of case based surveillance in Zimbabwe
Simbarashe Chimhuya1*, Portia Manangazira2, Arnold Mukaratirwa3, Pasipanodya Nziramasanga3, Chipo Berejena3,
Annie Shonhai3, Mary Kamupota4, Regina Gerede4, Mary Munyoro5, Douglas Mangwanya6,
Christopher Tapfumaneyi7, Charles Byabamazima8, Eshetu Messeret Shibeshi8 and Kusum Jackison Nathoo1Abstract
Background: Rubella is a disease of public health significance owing to its adverse effects during pregnancy and
on pregnancy outcomes. Women who contract rubella virus during pregnancy may experience complications such
as foetal death or give birth to babies born with congenital rubella syndrome. Vaccination against rubella is the
most effective and economical approach to control the disease, and to avoid the long term effects and high costs
of care for children with congenital rubella syndrome as well as to prevent death from complications. Zimbabwe
commenced rubella surveillance in 1999, despite lacking a rubella vaccine in the national Expanded Programme on
Immunization, as per the World Health Organization recommendation to establish a surveillance system to estimate
the disease burden before introduction of a rubella vaccine. The purpose of this analysis is to describe the disease
trends and population demographics of rubella cases that were identified through the Zimbabwe national measles
and rubella case-based surveillance system during a 5-year period between 2007 and 2011.
Methods: Data from the Zimbabwe National Measles Laboratory for the 5-year study period were analysed for age,
sex, district of origin, seasonality, and rubella IgM serostatus.
Results: A total of 3428 serum samples from cases of suspected measles in all administrative districts of the country
were received by the laboratory during this period. Cases included 51% males and 49% females. Of these, 2999
were tested for measles IgM of which 697 (23.2%) were positive. Of the 2302 measles IgM-negative samples, 865
(37.6%) were rubella IgM-positive. Ninety-eight percent of confirmed rubella cases were children younger than
15 years of age. Most infections occurred during the dry season.
Conclusions: The national case-based surveillance revealed the disease burden and trends of rubella in Zimbabwe.
These data add to the evidence for introducing rubella-containing vaccine into the national immunization
programme.
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Rubella is a disease of public health significance, largely
owing to the teratogenic effects of the virus, and is char-
acterized by multiple birth defects known as congenital
rubella syndrome (CRS). Common birth defects are ocu-
lar (cataracts, retinitis, microphthalmia, and glaucoma),
hearing impairment, heart defects (pulmonary stenosis,* Correspondence: chimhuya.simbarashe@gmail.com
1Department of Paediatrics and Child Health, University of
Zimbabwe-College of Health Sciences, Mazoe Street, A178 Avondale, Harare,
Zimbabwe
Full list of author information is available at the end of the article
© 2015 Chimhuya et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.persistent ductus arteriosus), microcephaly, developmen-
tal delay, mental retardation, bone alterations, and dam-
age to the liver and spleen [1]. Other adverse outcomes
of rubella infection in early pregnancy or just before
conception include foetal resorption, spontaneous abor-
tion and intrauterine foetal death. It is estimated that
the majority (90%) of infants with CRS are born to
women who were infected by rubella virus in the first
10 weeks of pregnancy [2].
It is estimated that more than 100,000 infants world-
wide are born with CRS each year. Africa, the Western
Pacific and Southeast Asia are regions known to havetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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estimated to be between 0.1 and 0.2 cases per 1000 live
births. This incidence rises to 1–4 cases per 1000 live
births during rubella outbreaks. In the prevaccine era, ru-
bella was responsible for over 11,000 foetal deaths and
there were 20,000 infants born with CRS in the United
States during an epidemic between 1964 and 1965. Routine
rubella vaccination in the US began in 1969, and by 2004,
the country was declared free of endemic rubella [5].
Nearly 136,000 cases of rubella were reported in the
Americas in 1998, predominantly in southern regions. In
2003, Pan American Health Organization member coun-
tries established a goal to eliminate rubella and CRS
from the Western Hemisphere by 2010, under a back-
ground of outbreaks during the 1990s [6]. This goal was
achieved when the last cases of endemic rubella were re-
ported in 2009, and the eight cases reported in Canada
and the US were found to be imported [7].
The World Health Organization (WHO) European Re-
gion set a measles and rubella elimination goal by 2010
(resolution EUR/RC55/R7 of 2005) under a background of
rising rubella incidence, especially in central and Eastern
Europe and the post-Soviet states [8]. Through increased
immunization efforts, the incidence of rubella was reduced
from 233 cases in 2005 to 13 in 2009 per 100,000
population [9].
Meanwhile, rubella has been circulating widely in Africa.
Estimates of rubella prevalence are obtained primarily from
combined measles/rubella case-based surveillance con-
ducted according to the guidelines of the WHO Regional
Office for Africa (WHO/AFRO) [10]. Goodson et al. ana-
lysed rubella seroprevalence data from Africa from 17
published reports and estimated that 1–29% of adults and
6–16% of women of child-bearing age (15 to 49 years) in
the region are susceptible to rubella [11]. The majority
(95%) of rubella cases reported in this survey had occurred
in children up to 14 years of age.
In Zimbabwe, surveillance for rubella was introduced
in 1999 through the existing measles surveillance sys-
tem. The measles case definition (children and adults
presenting to health facilities with rash and fever plus at
least one of the following: coryza, conjunctivitis or
cough, or any person in whom a clinician suspects mea-
sles) was also adopted for rubella surveillance. All sam-
ples negative for measles IgM antibodies by serological
testing are subsequently tested for rubella. This ap-
proach may underestimate the burden of rubella be-
cause the surveillance is not primarily designed to
identify rubella but rather to identify measles. Some ru-
bella infections are missed because they do not meet the
“suspected measles” case definition. The WHO/AFRO
measles surveillance guidelines require that the testing
algorithm exclude measles IgM-positive cases from ru-
bella screening.In 1969, a serosurvey of nine common respiratory vi-
ruses, including rubella virus, was completed over a
period of 3 months, among 112 children and adults of
the Korekore tribe in northern Zimbabwe who visited a
local mission hospital. Blood samples were tested for ru-
bella antibodies using the haemagglutination inhibition
assay. The study found 88% rubella seropositivity among
the study population [12]. This high rate of seropositivity
suggested a recent rubella outbreak around the time of
the serosurvey. A measles and rubella epidemic occurred
in Zimbabwe in 1977–1978, which resulted in sudden
detection of an unexpected number of cases of rubella
embryopathy in infants born at a major African referral
hospital [13]. It was suggested that this epidemic was
fuelled by population movement because of the escal-
ation of war during the same period. In the literature, it
has been suggested that rubella epidemics usually occur
at intervals of approximately 7–10 years. This is also
supported by data from The Gambia where epidemics
were serologically diagnosed during 1963–1964 and
1973–1974 [14].
Owing to the existing burden of rubella in some regions
of the world, the WHO recommends introduction of
rubella-containing vaccines as a strategy to control the dis-
ease. Rubella vaccination programmes are economically
justifiable and have demonstrated cost-effectiveness. Pub-
lished economic analyses for the period between 1980 and
2010 indicate that the annual cost (inflation-adjusted 2012
US$) for the care of a patient with CRS in middle-income
countries ranges from US$4,200 in Brazil to US$58,000 in
Panama, whereas the lifetime cost for the care of a patient
with CRS in high-income countries (inflation-adjusted
2012 US$) is estimated to be US$139,900 in Oman and
over US$200,000 in the United States [15].
The WHO recommends that prior to introduction of
rubella vaccine to national immunization programmes,
rubella surveillance should be implemented through the
existing measles surveillance system to estimate the dis-
ease burden [3]. In line with the WHO strategy for ru-
bella vaccination in Africa, our analysis of data from
Zimbabwe’s combined measles/rubella case-based sur-
veillance system aims to describe the trends and popula-
tion demographics of children and adolescents with
rubella in the country, who were identified through its
national surveillance system during a 5-year period be-
tween 2007 and 2011.
Methods
Sample collection and laboratory procedures
During the study period, blood samples were collected
from suspected measles cases detected within 14 days of
rash onset, according to the standard WHO/AFRO case
definitions for measles and rubella surveillance. All age
groups were investigated, including adults. According to
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WHO guidelines for measles surveillance [10], all sus-
pected cases should be tested for measles IgM anti-
bodies. However, if an outbreak of measles is suspected,
only the first five cases from a cluster of suspected
measles cases should be tested for measles IgM antibodies.
If three or more of these cases test IgM-positive, this is
considered a laboratory-confirmed measles outbreak.
When an outbreak is confirmed, no further samples
should be collected from that district or area until
30 days after initial confirmation of the outbreak. Additional
suspected cases of measles detected within 30 days in the
same district or area are line listed as epidemiologically
linked or clinically confirmed measles cases. A regional out-
break of measles in seven southern African countries in-
cluding Zimbabwe was confirmed during 2009–2010
[17]. Sample collection and testing were therefore re-
stricted during this time. Supplementary measles vac-
cination activities were subsequently carried out to
contain this outbreak.
At first contact with a suspected case, about 1–5-ml
blood was collected by venipuncture into a sterile
anticoagulant-free tube. The blood was allowed to clot
and then centrifuged at 3000 rpm for 5 minutes to sep-
arate the serum. If there was no centrifuge at the health
centre, the blood specimen was kept in a refrigerator
until there was complete retraction of the clot from the
serum. The serum was transferred aseptically to a sterile
vial, and then stored at 2–8C for no more than 3 days
before being transported to the testing laboratory in cold
boxes at the same temperature. All blood samples were
tested at the National Virology Reference Laboratory
(NVRL), which houses the National Measles Laboratory.
The latter is accredited by the WHO Global Measles
and Rubella Laboratory Network (LabNet) and thus gen-
erates credible results for the programme.Serological testing for rubella virus IgM antibodies
Serum samples were stored at −30°C (±2°C) and tested
within 7 days. Enzyme-linked immunosorbent assay
(ELISA) for rubella-specific IgM antibody was performed
according to the manufacturer’s protocol (Enzygnost®
Anti-Rubella Virus/IgM kit; Siemens AG, Erlangen,
Germany). A micropipette (Gilson International B.V.,
Den Haag, the Netherlands) was used to manually dis-
pense the samples and reagents. Twenty microlitres of
serum were used in the test. Test plates were washed
using a microplate washer (ELx50; BioTek UK, Bedfordshire,
UK). Optical densities were read at 450 nm with a 630-nm
reference filter using an ELISA reader (ELx808i; BioTek
UK). All samples were tested once and those produ-
cing equivocal results were not retested owing to a
lack of resources.Ethical issues
Zimbabwe’s combined measles/rubella surveillance is a
national programme approved by the Ministry of Health
and Child Care, which is supported by WHO/AFRO as
part of the global goal to control and eliminate measles
and rubella. All procedures for obtaining patient infor-
mation and specimens were performed according to the
WHO/AFRO measles/rubella surveillance protocol. Al-
though written consent from suspected cases (or their
parents, in the case of minor children) is not required
for purposes of the national surveillance system, relevant
information was provided and verbal permission sought
before collection of samples.
Results
During the 5 years under review, a total of 3428 samples
from suspected measles cases were received by the Na-
tional Measles Laboratory, from all districts and cities of
Zimbabwe. Most cases originated from the city of Harare
(655; 19.1%) and the adjacent district of Goromonzi (108;
3.2%). Other districts had less than 100 suspected cases
during each year of the study period. The geographical dis-
tribution of these cases is shown in Figure 1. Of samples
from suspected measles cases, 2999 (87.5%) were tested
for measles IgM antibodies; 429 samples were not tested
because they were collected within 30 days after confirm-
ation of a regional measles outbreak during 2009–2010.
Cases comprised 1757 (51.2%) males and 1671 (48.8%)
females.
Of the 3428 samples received by the laboratory, 2302
(67.2%) were eligible for rubella testing. A total of 865
(37.6%) were rubella IgM-positive, as shown in Table 1.
During the measles outbreak in 2009–2010, laboratory
detection of rubella IgM antibody was low. Although
there was no confirmed case of measles after this out-
break, the number of samples from suspected measles
cases received by the laboratory remained high (Figure 2).
Of the 910 samples received in 2011, all were negative
for measles antibodies whereas 50.7% tested positive for
rubella IgM.
The incidence of laboratory-confirmed rubella showed
an increase in children over 3 years of age, followed by a
decline after 12 years (Figure 3). Peak incidence oc-
curred between 7 and 12 years, and 98% of confirmed
cases were under 15 years old; age was not specified in
fifteen cases (1.7%).
There was a seasonal pattern in the occurrence of la-
boratory confirmed rubella, with peaks in the late spring
(October to November) as shown in Figure 4. There was
a sharp decline in December and incidence remained
low through April of each year. December is usually
characterized by heavy rainfall and the rainy season lasts
through April; May to mid-November is generally dry.
Small peaks were observed in autumn (March to April).
Figure 1 Spot map of Zimbabwe showing the distribution of laboratory confirmed rubella cases (2007–2011). The map of Zimbabwe
showing district boundaries; one dot represents one confirmed case of rubella. This distribution shows that all districts were affected with
tendency to cluster around urban areas owing to higher population densities in urban compared to rural areas.
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among the suspected cases was 37.5% (95% CI = 34.2-40.8)
during rainy seasons and 62.5% (95% CI = 59.2-65.8) during
dry seasons.
Discussion
Concurrent measles and rubella surveillance enabled de-
tection of rubella trends in Zimbabwe. In the current
analysis, we observed that during the measles outbreak
of 2009–2010, laboratory detection of rubella was low
(10.5–27.7%) compared with the years 2007, 2008, and
2011, during which the incidence of laboratory-
confirmed rubella was 44–50.7%. This observation couldTable 1 Distribution of suspected and confirmed measles and






2007 242 242 1 (0.4)
2008 158 158 0 (0)
2009 412 400 125 (3
2010 1706 1296 571 (4
2011 910 903 0 (0)
Total 3428 2999 697 (2
The table shows a breakdown by year of number of samples from suspected measl
system during 2007–2011. Samples received at the National Measles Laboratory in
positive along with their percentages (%) are indicated. Samples that were negative
together with their percentages (%) are also indicated. In 2007, for example, only 1
measles negative samples, 106 (44%) were positive for rubella.be a reflection of the restricted laboratory testing during
a measles outbreak. It also confirms observations from
other studies that when the prevalence of measles is low
the incidence of true measles among suspected cases
meeting the case definition is low. Under such condi-
tions measles-like illness is more likely due to other
causes such as rubella. It may also suggest that the ef-
fectiveness of using the measles clinical case definition
to detect rubella is poorer during a measles outbreak.
The latter explanation is supported by Helfand et al.
who carried out a 3-month survey to compare accuracy
of the measles case definition with laboratory diagnosis









1.3) 275 29 (10.5)
4.1) 725 201 (27.7)
903 458 (50.7)
3.2) 2302 865 (37.6)
es cases identified through the national measles and rubella surveillance
good condition were tested first for measles and the numbers that were
for measles were subsequently tested for rubella and the total positives,










2007 2008 2009 2010 2011
Total suspected measles Rubella IgM positive Rubella IgM negative
Figure 2 Number of rubella IgM positive and negative samples among suspected measles cases, 2007–2011, Zimbabwe. An outbreak of
measles was confirmed in 2009 and supplementary immunization activities started. The outbreak was controlled by 2010. In 2011 the number
samples from suspected measles cases referred to the laboratory for testing remained high. Fifty percent of these cases were positive for rubella.
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ples obtained from 105 children (aged 1 to17 years)
who presented to health facilities with suspected mea-
sles were tested for both measles and rubella-specific
IgM. Of the 96 children who met the clinical case defin-
ition for measles, 72% were positive for measles IgM
and 23% positive for rubella IgM; 3% were positive for
both viruses and 2% were negative for both. Although
























Figure 3 Age incidence of laboratory confirmed rubella, 2007–2011, Z
each year. The incidence rises from 3 to 11 years of age and starts to decli
These represent susceptible build-up in older age groups of the female po
inter-epidemic periods.comparison, the 23% rubella seropositivity rate is in
agreement with the rates observed during the measles
epidemic in our analysis.
In another survey in South Africa, Blackburn et al. also
found that rash-like illnesses fitting the surveillance cri-
teria for measles were far more likely to be rubella. In
this survey, 106 of 220 (48.2%) samples submitted for la-
boratory confirmation of measles were rubella IgM-
positive whereas only 12 (5.5%) were positive for measles10 11 12 13 14 15 16 17 18 19
(years)
09 2008 2007
imbabwe. The graph shows age incidence of rubella infection during
ne. Cases older than 15 years were also detected by the surveillance.
pulation following local extinction of rubella in the
Figure 4 Seasonal pattern of rubella infection in Zimbabwe. The graph shows monthly incidence of laboratory confirmed rubella during a
five year period. In each year larger peaks occurred during the dry months particularly late spring (October and November).
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were positive for human herpesvirus 6 and parvovirus,
respectively [19]. This 48.2% seropositivity rate for ru-
bella is also in keeping with rates observed in Zimbabwe
when measles incidence rates were zero percent per
year.
The WHO clinical case definition used for measles
surveillance (fever plus maculopapular rash plus cough,
coryza or conjunctivitis) has limited sensitivity for ru-
bella [20,21]. The positive predictive value of the clinical
case definition for measles is dependent upon disease in-
cidence. As measles incidence increases, the case defin-
ition becomes better at predicting measles. It is also
known that up to 50% of children with rubella infections
do not present with rash [22]. Rubella infection may
present without fever and children often have minimal
or no constitutional symptoms at all. The rash may be
difficult to detect in people with dark skin. Several other
agents may also cause measles-like rash such as parvo-
virus B19, adenovirus, human herpesvirus, enterovirus,
and streptococcal bacteria. Therefore, it is likely that a
significant proportion of children with rubella may have
been missed through the existing surveillance system be-
cause it is designed to detect measles and not rubella.
Owing to limitations of the WHO case definition for
identifying cases of rubella, modified definitions have been
adopted in other regions that have set rubella elimination
targets, so as to enhance detection. The following definition
was used by the Pan American Health Organization forrubella surveillance as the region moved toward an elimin-
ation target: a suspected case is one in which a health
worker suspects rubella [23]. The European Centre for Dis-
ease Prevention and Control also adopted a modified defin-
ition, namely, any person with sudden onset of generalized
maculopapular rash and at least one of the following: cer-
vical adenopathy, suboccipital adenopathy, post-auricular
adenopathy, arthralgia or arthritis [24]. As Zimbabwe and
other African countries work toward introducing rubella-
containing vaccines and plan elimination goals, a modified
case definition will need to be considered so as to improve
detection rates.
The data in the present study also show that although
rubella infections occurred throughout each year, they
were characterized by large peaks in the months from
August to November, which coincide with the dry and
hot months in Zimbabwe. Smaller peaks were observed
in March, which is normally a hot and rainy period. Sea-
sonal variations of rubella incidence were noted in the
United States and temperate regions during the prevac-
cine era, with major peaks occurring in the spring. Fac-
tors that have been implicated in the incidence of
rubella include age (mean age of highest transmission
rates 3–11 years), critical community size (population
size required for the infection to persist locally is ap-
proximately 1,000,000, although it could be less because
of underreporting), seasonality (incidence is highest in
the spring), birth rate (incidence is high in communities
with high birth rates), heterogeneity of vaccination
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with aggregation of children in school and decreases
during school vacation) [27]. Geographical location plays
an uncertain role. In one study in Peru, for example, the
incidence of CRS was related to distance from the
coastal region of Lima but no differences were found be-
tween an urban versus a rural setting in Argentina,
Brazil, Chile, Jamaica, Trinidad and Uruguay [28]. Gen-
der is not a significant factor for transmission. In our
analysis, the age group most affected was 3–15 years old
and there was no sex predilection noted.
Adolescents and young reproductive-age women were
also affected during our study period. This may repre-
sent susceptible build-up in older age groups of the fe-
male population following local extinction of rubella in
the inter-epidemic periods. This is of concern because in
the absence of a routine and sustained high-coverage
vaccination programme against rubella, there is high risk
of giving birth to babies with CRS among this popula-
tion of women. Our surveillance did not routinely col-
lect pregnancy related data on reproductive age women
or provide follow up because it was primarily designed
to identify measles (not rubella) in 6 months to 15 years
old. Collection of samples at health facility level was
triggered by a suspicion of measles. It is therefore not
known whether some of the adolescent girls and repro-
ductive age women older than 15 years of age were preg-
nant at the time of diagnosis. In order to obtain this
information the measles case report form used in the
surveillance needs to be modified to include a pregnancy
test for women older than 15 years who present with
measles-like febrile rash illness.
The apparent higher disease incidence in Zimbabwe’s
capital, Harare, and its peri-urban communities is more
likely a reflection of higher population density and the
dynamics of disease reporting in urban areas compared
to rural areas. Remote areas may experience unique
reporting challenges such as poor transportation, poor
accessibility to health facilities, lower levels of health
worker awareness and different health-seeking behaviour
of community residents.
Conclusions
Rubella virus circulates in all districts of Zimbabwe, mainly
affecting children below the age of 15 years. Most cases
occur during the dry season. Further studies are needed to
characterize the rubella genotypes circulating in Zimbabwe,
with a view to determine endemicity and trends so as to
introduce and enhance vaccination interventions.
Additional file
For more detail to readers an additional excel dataset file
associated with all analysis in this articles is provided
(see Additional file 1).Additional file
Additional file 1: This is Excel file containing dataset associated
with all analysis in this article. All variables that identify patients have
been removed from the file. Variables included in this dataset are; date of
onset, date of specimen collection, sex, age in years and months, measles
IgM result and rubella IgM result. A result key is also provided.
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